Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Cross-Over Study of QD and BID Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Revefenacin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Theravance; Theravance Biopharma
- 05 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Sep 2014 This trial will complete in the 4th quarter of 2014, according to a Theravance Biopharma media release.
- 04 Sep 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov